Vergoeding 2017-2021 voor ATC-subgroep J05AF : Nucleoside en nucleotide reverse-transcriptaseremmers
- Raming voor de totale Zvw-populatie
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| J05AF01 Zidovudine (Retrovir ®) | 43.575 | 32.785 | 19.823 | 13.729 | 18.608 |
| J05AF02 Didanosine | 38.300 | 648 | . | . | . |
| J05AF04 Stavudine | 905 | . | . | . | . |
| J05AF05 Lamivudine (Epivir ®) | 592.810 | 529.190 | 424.470 | 301.640 | 230.010 |
| J05AF06 Abacavir (Ziagen ®) | 585.840 | 505.680 | 385.420 | 302.520 | 258.500 |
| J05AF07 Tenofovirdisoproxil (Viread ®) | 6.491.200 | 2.534.500 | 994.490 | 876.800 | 675.300 |
| J05AF08 Adefovir (Hepsera ®) | 377.140 | 340.800 | 246.130 | 190.890 | 159.660 |
| J05AF09 Emtricitabine (Emtriva ®) | 79.988 | 57.383 | 50.287 | 52.636 | 43.997 |
| J05AF10 Entecavir (Baraclude ®) | 7.478.300 | 3.425.200 | 1.484.400 | 1.641.200 | 1.324.000 |
| J05AF11 Telbivudine (Sebivo ®) | 22.045 | 24.060 | 20.327 | 2.504 | . |
| J05AF13 Tenofoviralafenamide (Vemlidy ®) | 58.306 | 519.990 | 1.101.300 | 1.595.100 | 1.785.600 |
| Totaal | 15.768.409 | 7.970.236 | 4.726.647 | 4.977.019 | 4.495.675 |